Apellis Pharmaceuticals, Inc.
http://www.apellis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Apellis Pharmaceuticals, Inc.
Dyne Reports Progress Building Next-Generation Exon Skipping Franchise In DMD
The company reported updated data from the Phase I/II DELIVER trial testing DYNE-251 in patients with Duchenne muscular dystrophy (DMD) and announced leadership changes.
Finance Watch: Fresh Cash For Life Science Firms From venBio, Symbiotic
Private Company Edition: Symbiotic Capital emerged with a $600m-plus fund to provide credit for private and public companies, while venBio raised a $528m fund. Also, Outpace Bio raised $144m, Jade Biosciences launched with $80m and MBX Biosciences raised $63.5m.
Apellis’s Pegcetacoplan Hits 'Grand Slam' Scenario In Rare Kidney Disease
A Phase III trial testing pegcetacoplan in patients with two rare kidney diseases demonstrated impressive efficacy, outperforming what Novartis showed with Fabhalta in a similar trial.
Avidity Is The Mid-Cap Rising Star Of 2024 So Far
New modalities and potential best-in-class challengers have excited investors in 2024 to date, but companies whose drugs have underperformed on the market have been punished.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice